Braxia Scientific reports positive early results from Phase 2 psilocybin-assisted depression therapy
Channel:
Subscribers:
56,400
Published on ● Video Link: https://www.youtube.com/watch?v=ed3ukfdG-iI
Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company is reporting preliminary results from the Phase 2 randomized clinical trial to evaluate the feasibility, safety, tolerability and efficacy of multidose psilocybin-assisted therapy for treatment-resistant depression.
Dr McIntyre told Proactive the study showed clinically meaningful improvements in depression severity. Complete analysis of antidepressant efficacy and secondary outcomes pending; this trial will be completed by December, 2022, at which point the full analysis will be completed and submitted for publication.
Other Videos By Proactive Investors
Tags:
Investors
investing
investor
economy
stocks
stock market
ftse100
nasdaq
nyse
cse
tsx
tsx-v
otc market
finance
banking
wealth management
asset management
wall street
economics
mining
oil and gas
energy
precious metals
biotech
health
pharma
pharamceutical
cbd
cryptocurrency
bitcoin
blockchain
cannabidoil
cannabis stock
Proactive
ProactiveInvestors
Proactive Investors
shares
trading
money
business
china
china economy
USA
US Economy
EU
European Union
Brexit
YouTube
How To